m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism

Molecular Cancer

Review

Shi-Wei Yue¹  Wei Zhang¹  Bi-Xiang Zhang¹  Hui-Fang Liang¹  Hong-Fei Su¹  Chu Luo¹  Hai-Ling Liu¹ 

[1] Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Hubei Key Laboratory of Hepato‑Pancreatic‑Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Clinical Medical Research Center of Hepatic Surgery at Hubei Province, Wuhan, China;

关键词: m6A;    Tumor;    Glycolysis;    Tumor therapy;   

DOI  :  10.1186/s12943-023-01841-8

 received in 2023-06-27, accepted in 2023-08-05,  发布年份 2023

来源: Springer

【 摘 要 】

Glycolytic reprogramming is one of the most important features of cancer and plays an integral role in the progression of cancer. In cancer cells, changes in glucose metabolism meet the needs of self-proliferation, angiogenesis and lymphangiogenesis, metastasis, and also affect the immune escape, prognosis evaluation and therapeutic effect of cancer. The n6-methyladenosine (m6A) modification of RNA is widespread in eukaryotic cells. Dynamic and reversible m6A modifications are widely involved in the regulation of cancer stem cell renewal and differentiation, tumor therapy resistance, tumor microenvironment, tumor immune escape, and tumor metabolism. Lately, more and more evidences show that m6A modification can affect the glycolysis process of tumors in a variety of ways to regulate the biological behavior of tumors. In this review, we discussed the role of glycolysis in tumor genesis and development, and elaborated in detail the profound impact of m6A modification on different tumor by regulating glycolysis. We believe that m6A modified glycolysis has great significance and potential for tumor treatment.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

40798_2023_622_Article_IEq20.gif

Fig. 8